<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLINDAMYCIN HYDROCHLORIDEÂ - clindamycin hydrochlorideÂ capsuleÂ </strong><br>RedPharm Drug Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>WARNING</h1>To reduce the development of drug-resistant bacteria and maintain the 
effectiveness of clindamycin hydrochloride and other antibacterial drugs, 
clindamycin hydrochloride should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
that are proven or strongly suspected to be caused by bacteria.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all 
antibacterial agents, including clindamycin, and may range in severity from mild 
to life-threatening. Therefore, it is important to consider this diagnosis in 
patients who present with diarÂ­rhea subsequent to the administration of 
antibacterial agents.</span><br><br>Because clindamycin therapy has been 
assoÂ­ciated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may end fatally, it should be reserved for 
serious infecÂ­tions where less toxic antimicrobial agents are inappropriate, as 
described in the <span class="Bold"><a href="#section-"> INDICAÂ­TIONS AND 
USAGE</a>Â </span>section. It should not be used in patients with nonbacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as most <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>. Treatment with 
antibacterial agents alters the normal flora of the colon and may permit 
overÂ­growth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile </span>is one primary cause of 
â€œantibiotic-associated colitisâ€?.<br><br>After the diagnosis of pseudomembranous 
<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> has been established, therapeutic measures should be initiated. Mild 
cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. 
In moderate to severe cases, consideration should be given to manÂ­agement with 
fluids and electrolytes, protein supplementation, and treatment with an 
antiÂ­bacterial drug clinically effective against <span class="Italics">C. 
difÂ­</span><span class="Italics">ficile </span><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.<br><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, 
and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> have been observed to begin up to several weeks 
following cessation of therapy with clindamycin.</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin. 
Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution 
of the 7(R)-hydroxyl group of the parent compound lincomycin.<br>Â <br>The 
chemical name for clindamycin hydrochloride is Methyl 
7-chloro-6,7,8-trideoxy-6-(1-methyl-<span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo</span>-Î±-D-<span class="Italics">galacto</span>-octopyranoside 
monohydrochloride. The structural formula is represented below:<div class="Figure"><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=63a0466c-af7d-4696-a950-19b73b55a65a&amp;name=image1.jpg"></div>
<br><span class="Bold"> C<span class="Sub">18</span>H<span class="Sub">33</span>ClN<span class="Sub">2</span>O<span class="Sub">5</span>Sâ€¢HCl</span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  
<span class="Bold">M.W. 461.45</span><br><br>Clindamycin hydrochloride capsules, 
USP contain clindamycin hydrochloride equivalent to 150 mg or 300 mg of 
clindamycin. Each capsule also contains the following inactive ingredients: 
lactose monohydrate, corn starch, talc, and magnesium stearate. The empty hard 
gelatin capsule shell consists of FD and C Blue No. 1, titanium dioxide, gelatin 
and sodium lauryl sulphate. In addition 150 mg also contains yellow iron oxide. 
The capsules are printed with edible ink containing black iron oxide and 
shellac. <br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="#section-"></a>Human Pharmacology<br>Serum level studies with a 
150 mg oral dose of clindamycin hydrochloride in 24 normal adult volunteers 
showed that clindamycin was rapidly absorbed after oral administration. An 
average peak serum level of 2.5 mcg/mL was reached in 45 minutes; serum levels 
averaged 1.51 mcg/mL at 3 hours and 0.7 mcg/mL at 6 hours. Absorption of an oral 
dose is virtually complete (90%), and the concomitant administration of food 
does not appreciably modify the serum concentrations; serum levels have been 
uniform and predictable from person to person and dose to dose. Serum level 
studies following multiple doses of clindamycin hydrochloride for up to 14 days 
show no evidence of accumulation or altered metabolism of drug.<br>Â <br>Serum 
half-life of clindamycin is increased slightly in patientsÂ  withÂ  markedlyÂ  
reduced renal function. Hemodialysis and peritoneal dialysis are not effective 
in removing clindamycin from the serum.<br>Â <br>Concentrations of clindamycin in 
the serum increased linearly with increased dose. Serum levels exceed the MIC 
(<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>) for most indicated organisms for at least six 
hours following administration of the usually recommended doses. Clindamycin is 
widely distributed in body fluids and tissues (including bones). The average 
biological half-life is 2.4 hours. Approximately 10% of the bioactivity is 
excreted in the urine and 3.6% in the feces; the remainder is excreted as 
bioinactive metabolites.<br>Â <br>Doses of up to 2 grams of clindamycin per day 
for 14 days have been well tolerated by healthy volunteers, except that the 
incidence of gastrointestinal side effects is greater with the higher 
doses.<br>Â <br>No significant levels of clindamycin are attained in the 
cerebrospinal fluid, even in the presence of inflamed 
meninges.<br>Â <br>Pharmacokinetic studies in elderly volunteers (61 to 79 years) 
and younger adults (18 to 39 years) indicate that age alone does not alter 
clindamycin pharmacokinetics (clearance, elimination half-life, volume of 
distribution, and area under the serum concentration-time curve) after IV 
administration of clindamycin phosphate. After oral administration of 
clindamycin hydrochloride, elimination half-life is increased to approximately 4 
hours (range 3.4 to 5.1 h) in the elderly compared to 3.2 hours (range 2.1 to 
4.2 h) in younger adults. The extent of absorption, however, is not different 
between age groups and no dosage alteration is necessary for the elderly with 
normal hepatic function and normal (age-adjusted) renal function.<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Microbiology<br>Clindamycin inhibits bacterial 
protein synthesis by binding to the 50S subunit of the ribosome. It has activity 
against Gram-positive aerobes and anaerobes as well as the Gram-negative 
anaerobes. Clindamycin is bacteriostatic. Cross-resistance between clindamycin 
and lincomycin is complete. Antagonism <span class="Italics">in vitro </span>has 
been demonstrated between clindamycin and erythromycin.<br>Â <br>Clindamycin has 
been shown to be active against most of the isolates of the following 
microorganisms, both <span class="Italics">in vitro </span>and in clinical 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, as described in the <span class="Bold"><a href="#section-"> INDICATIONS AND USAGE</a></span>Â section.<br><span class="Bold"><br>Gram-positive aerobes</span><br>Â <br><span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Streptococcus pneumoniae 
</span>(penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Streptococcus 
pyogenes</span><br>Â <br><span class="Bold">Anaerobes</span><br>Â <br><span class="Italics">Prevotella melaninogenica</span><br><span class="Italics">Fusobacterium necrophorum</span><br><span class="Italics">Fusobacterium nucleatum</span><br><span class="Italics">Peptostreptococcus anaerobius</span><br><span class="Italics">Clostridium perfringens</span><br>Â <br>The following <span class="Italics">in vitro </span>data are available, but their clinical 
significance is unknown. At least 90% of the following microorganisms exhibit an 
<span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less 
than or equal to the susceptible breakpoint for clindamycin. However, the safety 
and effectiveness of clindamycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these 
microorganisms have not been established in adequate and well-controlled 
clinical trials.<br>Â <br><span class="Bold">Gram-positive aerobes</span><br>Â <br><span class="Italics">Staphylococcus epidermidis 
</span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Streptococcus 
agalactiae</span><br><span class="Italics">Streptococcus anginosus</span><br><span class="Italics">Streptococcus oralis</span><br>Streptococcus 
mitis<br>Â <br><span class="Bold">Anaerobes</span><br>Â <br><span class="Italics">Prevotella intermedia</span><br>Prevotella 
bivia<br>Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span><br>Micromonas (â€œPeptostreptococcusâ€?) 
micros<br>Finegoldia (â€œPeptostreptococcusâ€?) magna<br>Actinomyces 
israelii<br>Clostridium clostridioforme<br>Eubacterium lentum<br><a href="http://"></a>Susceptibility Testing Methods<span class="Bold"><br>NOTE: </span>Susceptibility testing by dilution methods requires 
the use of clindamycin susceptibility powder.<br>Â <br>When available, the 
results of <span class="Italics">in vitro</span> susceptibility tests should be 
provided to the physician as periodic reports that describe the susceptibility 
profile of nosocomial and community-acquired pathogens. These reports should aid 
the physician in selecting the most effective antimicrobial.<br>Â <br>Dilution 
Techniques<br>Â <br>Quantitative methods are used to determine antimicrobial 
<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the 
susceptibility of bacteria to antimicrobial compounds. The MICs should be 
determined using a standardized procedure. Standardized procedures are based on 
a dilution method (broth and agar)<span class="Sup">1,2,3</span> or equivalent 
with standardized inoculum concentrations and standardized concentrations of 
clindamycin powder. The MIC values should be interpreted according to the 
criteria provided in Table 1.<br>Â <br>Diffusion Techniques<br>Â <br>Quantitative 
methods that require the measurement of zone diameters also provide reproducible 
estimates of the susceptibility of bacteria to antimicrobial compounds. One such 
standardized procedure<span class="Sup">2,3</span> requires the use of 
standardized inoculum concentrations. This procedure uses paper disks 
impregnated with 2 mcg of clindamycin to test the susceptibility of 
microorganisms to clindamycin. The disk diffusion interpretive criteria are 
provided in Table 1.Â Â Â Â Â <br><a name="ibcf65864-4d1e-4b87-804a-2da1eba1c753"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 1. Susceptibility Interpretive Criteria for Clindamycin 
</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th>Pathogen</th>
<th colspan="6">Susceptibility Interpretive 
Criteria</th>
</tr>
<tr>
<th colspan="3">Minimal Inhibitory 
<br>Concentrations <br>(MIC in mcg/mL)</th>
<th colspan="3">Disk Diffusion <br>(Zone 
Diameters in mm)</th>
</tr>
<tr class="Last">
<th><br></th>
<th>S</th>
<th>I</th>
<th>R</th>
<th>S</th>
<th>I</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td>Â Â Â <span class="Italics">Staphylococcus</span> 
spp.<br>
</td>
<td>â‰¤0.5<br>
</td>
<td>1-2<br>
</td>
<td>â‰¥4<br>
</td>
<td>â‰¥21<br>
</td>
<td>15-20<br>
</td>
<td>â‰¤14<br>
</td>
</tr>
<tr>
<td>Â Â Â <span class="Italics">Streptococcus 
pneumoniae</span> andÂ <br>Â Â Â other <span class="Italics">Streptococcus 
</span>spp.<br>
</td>
<td>â‰¤0.25<span class="Sup">a</span><br>
</td>
<td>0.5<br>
</td>
<td>â‰¥1<br>
</td>
<td>â‰¥19<span class="Sup">b</span><br>
</td>
<td>16-18<br>
</td>
<td>â‰¤15<br>
</td>
</tr>
<tr class="Last">
<td>Â Â Â Anaerobic Bacteria<span class="Sup">c</span><br>
</td>
<td>â‰¤2<br>
</td>
<td>4<br>
</td>
<td>â‰¥8<br>
</td>
<td>NA<br>
</td>
<td>NA<br>
</td>
<td>NA<br>
</td>
</tr>
</tbody>
</table>
<br><span class="Sup">a</span> These 
interpretive standards for <span class="Italics">S. pneumoniae </span>and other 
<span class="Italics">Streptococcus </span>spp. are applicable only to tests 
performed by broth microdilution using cation-adjusted Mueller-Hinton broth with 
2 to 5% lysed horse blood inoculated with a direct colony suspension and 
incubated in ambient air at 35Â°C for 20 to 24 hours.<br><span class="Sup">b</span> 
These zone diameter interpretive standards are applicable only to tests 
performed using Mueller-Hinton agar supplemented with 5% sheep blood inoculated 
with a direct colony suspension and incubated in 5% CO<span class="Sub">2</span> 
at 35Â°C for 20 to 24 hours.<br><span class="Sup">c</span> These interpretive 
criteria are for all anaerobic bacterial pathogens; no organism specific 
interpretive criteria are available.<br>NA=Not applicable<br>Â <br>A report of 
â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the 
antimicrobial compound in the blood reaches the concentrations usually 
achievable. A report of â€œIntermediateâ€? indicates that the result should be 
considered equivocal, and, if the microorganism is not fully susceptible to 
alternative, clinically feasible drugs, the test should be repeated. This 
category implies possible clinical applicability in body sites where the drug is 
physiologically concentrated or in situations where high dosage of drug can be 
used. This category also provides a buffer zone that prevents small, 
uncontrolled technical factors from causing major discrepancies in 
interpretation. A report of â€œResistantâ€? indicates that the pathogen is not 
likely to be inhibited if the antimicrobial compound in the blood reaches the 
concentrations usually achievable; other therapy should be 
selected.<br>Â <br>Quality Control<br>Â <br>Standardized susceptibility test 
procedures require the use of quality control microorganisms to control the 
technical aspects of the test procedures. Standard clindamycin powder should 
provide the following range of values noted in Table 2. <span class="Bold">NOTE: 
</span>Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of organisms with 
intrinsic biological properties relating to resistance mechanisms and their 
genetic expression within bacteria; the specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for 
microbiological quality control are not clinically significant.Â <br><a name="id3231e76-080f-46fc-87a3-17d10dfcf52b"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 2. Acceptable Quality Control Ranges for Clindamycin to be Used 
in Validation of Susceptibility Test Results </span></caption>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th>
<br><br>QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></th>
<th colspan="2">Acceptable Quality Control 
Ranges</th>
</tr>
<tr class="Last">
<th>Minimum Inhibitory <br>Concentrations <br>(MIC in 
mcg/mL)</th>
<th>Disk Diffusion <br>(Zone Diameters in 
mm)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td>
<span class="Bold">Â When Testing Aerobic 
Pathogens</span><br>
</td>
<td>Â <br>
</td>
<td>Â <br>
</td>
</tr>
<tr>
<td>Â Â Â <span class="Italics">Staphylococcus 
aureus</span> ATCC 29213<br>
</td>
<td>Â Â Â Â Â  0.06â€“0.25<br>
</td>
<td>Â Â Â Â Â Â Â Â Â Â Â Â Â  NA<br>
</td>
</tr>
<tr>
<td>Â Â Â <span class="Italics">Staphylococcus 
aureus</span> ATCC 25923<br>
</td>
<td>Â Â Â Â Â  NA<br>
</td>
<td>Â Â Â Â Â Â Â Â Â Â Â Â Â  24â€“30<br>
</td>
</tr>
<tr>
<td>Â Â Â <span class="Italics">Streptococcus 
pneumoniae</span> ATCCÂ 49619<span class="Sup">d</span><br>
</td>
<td>Â Â Â Â  Â 0.03â€“0.12<span class="Sup">e</span><br>
</td>
<td>Â Â Â Â Â Â Â Â Â Â Â Â Â  19â€“25<span class="Sup">f</span><br>
</td>
</tr>
<tr>
<td>Â <span class="Bold">When Testing Strict 
Anaerobes</span><br>
</td>
<td>Â <br>
</td>
<td>Â <br>
</td>
</tr>
<tr>
<td>Â Â Â <span class="Italics">Bacteroides 
fragilis</span> ATCC 25285<br>
</td>
<td>Â Â Â Â Â  0.5â€“2<br>
</td>
<td>Â Â Â Â Â Â Â Â Â Â Â Â Â  NA<br>
</td>
</tr>
<tr>
<td>Â Â Â <span class="Italics">Bacteroides 
thetaiotaomicron</span> ATCCÂ 29741<br>
</td>
<td>Â Â Â Â Â  2â€“8<br>
</td>
<td>Â Â Â Â Â Â Â Â Â Â Â Â Â  NA<br>
</td>
</tr>
<tr class="Last">
<td>Â Â Â <span class="Italics">Eubacterium lentum</span> 
ATCC 43055<br>
</td>
<td>Â Â Â Â  Â 0.06â€“0.25<br>
</td>
<td>Â Â Â Â Â Â Â Â Â Â Â Â Â  
NA<br>
</td>
</tr>
</tbody>
</table>
<br>NA=Not applicable<br><span class="Sup">d</span> This organism may be used for validation of susceptibility 
test results when testing <span class="Italics">Streptococcus </span>spp. other 
than <span class="Italics">S. pneumoniae</span>.<br><span class="Sup">e</span> This 
quality control range for <span class="Italics">S. pneumoniae </span>is applicable 
only to tests performed by broth microdilution using cation-adjusted 
Mueller-Hinton broth with 2 to 5% lysed horse blood inoculated with a direct 
colony suspension and incubated in ambient air at 35Â°C for 20 to 24 
hours.<br><span class="Sup">f</span> This quality control zone diameter range is 
applicable only to tests performed using Mueller-Hinton agar supplemented with 
5% sheep blood inoculated with a direct colony suspension and incubated in 5% 
CO<span class="Sub">2</span> at 35Â°C for 20 to 24 hours.<br>Â <br>ATCC<span class="Sup">Â®</span> is a registered trademark of the American Type Culture 
Collection<a href="http://"></a><a href="http://"></a><a href="http://"></a>INDICATIONS AND USAGE<br>Clindamycin 
hydrochloride capsules are indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
caused by susceptible anaerobic <br><a href="#section-"></a><a href="#section-"></a>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>Clindamycin hydrochloride capsules are indicated in the treatment of serious 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible anaerobic bacteria. <br>Â <br>Clindamycin 
hydrochloride capsules are also indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of streptococci, pneumococci, and staphylococci. Its 
use should be reserved for penicillin-allergic patients or other patients for 
whom, in the judgment of the physician, a penicillin is inappropriate. Because 
of the risk of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, as described in the <span class="Bold"><a href="#Section_0">WARNING</a>Â </span>box, before selecting clindamycin the 
physician should consider the nature of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the suitability of 
less toxic alternatives (e.g., erythromycin).<br>Â <br><span class="Bold">Anaerobes:</span> Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span> such as 
<span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, anaerobic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">lung abscess</span>; serious skin and soft tissue 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>; intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> such as <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> and 
intra-<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span> (typically resulting from anaerobic organisms resident 
in the normal gastrointestinal tract); <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the female pelvis and 
genital tract such as <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, nongonococcal tuboovarian <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, pelvic 
<span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> and postsurgical vaginal cuff <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br>Â <br><span class="Bold">Streptococci:</span> Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>; serious 
skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span>.<br>Â <br><span class="Bold">Staphylococci:</span> 
Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>; serious skin and soft tissue 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.<br>Â <br><span class="Bold">Pneumococci:</span> Serious respiratory 
tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.<br>Â <br>Bacteriologic studies should be performed to determine 
the causative organisms and their susceptibility to clindamycin.<br>Â <br>To 
reduce the development of drug-resistant bacteria and maintain the effectiveness 
of clindamycin hydrochloride and other antibacterial drugs, clindamycin 
hydrochloride should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven 
or strongly suspected to be caused by susceptible bacteria. When culture and 
susceptibility information are available, they should be considered in selecting 
or modifying antibacterial therapy. In the absence of such data, local 
epidemiology and susceptibility patterns may contribute to the empiric selection 
of therapy.<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>Clindamycin hydrochloride capsules are contraindicated in individuals with a 
history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to preparations containing clindamycin or 
lincomycin.<br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>See <span class="Bold"><span class="Bold"><a href="#Section_0">WARNING</a></span></span>Â box.<span class="Bold"><br><br><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial 
agents, including clindamycin, and may range in severity from mild to 
life-threatening. Therefore, it is important to consider this diagnosis in 
patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of 
antibacterial agents.</span><br><br>Treatment with antibacterial agents alters 
the normal flora of the colon and may permit overgrowth of clostridia. Studies 
indicate that a toxin produced by <span class="Italics">Clostridium difficile 
</span>is one primary cause of â€œantibiotic-associated colitisâ€?.<br><br>After the 
diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures 
should be initiÂ­ated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to 
drug discontinuation alone. In moderate to severe cases, consideration should be 
given to manageÂ­ment with fluids and electrolytes, protein supplementaÂ­tion, and 
treatment with an antibacterial drug clinically effective against <span class="Italics">C. difficile </span><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.<br><br>A careful inquiry should be 
made concerning previous sensitivities to drugs and other allergens.<br><span class="Italics"><br>Usage in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></span>â€”Since clindamycin does not difÂ­fuse 
adequately into the cerebrospinal fluid, the drug should not be used in the 
treatment of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.<a href="http://"></a><a href="http://"></a>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>GeneralÂ  <br>Review of experience to date 
suggests that a subgroup of older patients with associated severe illness may 
tolerate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> less well. When clindamycin is indicated in these patients, 
they should be carefully monitored for change in bowel 
frequency.<br>Â <br>Clindamycin hydrochloride should be prescribed with caution 
in individuals with a history of gastrointestinal disease, particularly 
<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.<br>Â <br>Clindamycin hydrochloride should be prescribed with caution in 
<span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> individuals.<br>Â <br>Indicated surgical procedures should be performed in 
conjunction with antibiotic therapy.<br>Â <br>The use of clindamycin 
hydrochloride occasionally results in overgrowth of nonsusceptible 
organismsâ€”particularly yeasts. Should <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur, appropriate 
measures should be taken as indicated by the clinical 
situation.<br>Â <br>Clindamycin dosage modification may not be necessary in 
patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with moderate to severe liver disease, 
prolongation of clindamycin half-life has been found. However, it was postulated 
from studies that when given every eight hours, accumulation should rarely 
occur. Therefore, dosage modification in patients with liver disease may not be 
necessary. However, periodic liver enzyme determinations should be made when 
treating patients with severe liver disease.Â <br><br>Prescribing clindamycin 
hydrochloride in the absence of a proven or strongly suspected bacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the 
patient and increases the risk of the development of drug-resistant 
bacteria.<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7"></a><p></p>
<h1>Information for Patients</h1>Patients should be counseled that antibacterial drugs including clindamycin 
hydrochloride should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not 
treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When clindamycin hydrochloride 
is preÂ­scribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that 
although it is common to feel better early in the course of therapy, the 
medication should be taken exactly as directed. Skipping doses or not completing 
the full course of therapy may (1) decrease the effecÂ­tiveness of the immediate 
treatment and (2) increase the likelihood that bacteria will develop resistance 
and will not be treatable by clindamycin hydrochloride or other antibacteÂ­rial 
drugs in the future.<a href="http://"></a><a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8"></a><p></p>
<h1>Laboratory Tests</h1>During prolonged therapy, periodic liver and kidney function tests and blood 
counts should be performed.<br>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-9"></a><p></p>
<h1>Drug Interactions</h1>Clindamycin has been shown to have neuromuscular blocking properties that may 
enhance the action of other neuromuscular blocking agents. Therefore, it should 
be used with caution in patients receiving such agents.Â <br><br>Antagonism has 
been demonstrated between clindamycin and erythromycin <span class="Italics">in 
vitro</span>. Because of possible clinical significance, these two drugs should 
not be administered concurrently.<br>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-10"></a><p></p>
<h1>Carcinogenesis, Mutagenesis, Impairment of Fertility</h1>Long term studies in animals have not been performed with clindamycin to 
evaluate carcinogenic potential. Genotoxicity tests performed included a rat 
micronucleus test and an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> reversion test. Both tests were 
negative.Â <br><br>Fertility studies in rats treated orally with up to 300 
mg/kg/day (approximately 1.6 times the highest recommended adult human dose 
based on mg/m<span class="Sup">2</span>) revealed no effects on fertility or 
mating ability.<br>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-11"></a><p></p>
<h1>Pregnancy</h1>
<a href="http://"></a>Teratogenic effects<br>Pregnancy Category 
B<br>Â <br>Reproduction studies performed in rats and mice using oral doses of 
clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult 
human dose based on mg/m<span class="Sup">2</span>, respectively) or subcutaneous 
doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest 
recommended adult human dose based on mg/m<span class="Sup">2</span>, 
respectively) revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.<br>Â <br>There are, 
however, no adequate and well-controlled studies in pregnant women. Because 
animal reproduction studies are not always predictive of the human response, 
this drug should be used during pregnancy only if clearly needed.<a href="http://"></a><a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-12"></a><p></p>
<h1>Nursing Mothers</h1>Clindamycin has been reported to appear in breast milk in the range of 0.7 to 
3.8 mcg/mL.<br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-13"></a><p></p>
<h1>Pediatric Use</h1>When clindamycin hydrochloride is administered to the pediatric population 
(birth to 16 years), appropriate monitoring of organ system functions is 
desirable.<br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-14"></a><p></p>
<h1>Geriatric Use</h1>Clinical studies of clindamycin did not include sufficient numbers of patients 
age 65 and over to determine whether they respond differently from younger 
patients. However, other reported clinical experience indicates that 
antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (due to <span class="Italics">Clostridium difficile</span>) seen in association with most 
antibiotics occur more frequently in the elderly (&gt;60 years) and may be more 
severe. These patients should be carefully monitored for the development of 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.<br>Â <br>Pharmacokinetic studies with clindamycin have shown no 
clinically important differences between young and elderly subjects with normal 
hepatic function and normal (age-adjusted) renal function after oral or 
intravenous administration.<br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-15"></a><p></p>
<h1>ADVERSE REACTIONS</h1>The following reactions have been reported with the use of 
clindamycin.<br>Â <br><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, 
<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (see <span class="Bold"><a href="#Section_0">WARNING</a></span>Â box). The onset of 
<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial 
treatment (see <span class="Bold"><span class="Bold"><a href="#Section_5">WARNINGS</a></span></span>).<br>Â <br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Generalized mild to moderate 
morbilliform-like (maculopapular) <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> are the most frequently reported 
adverse reactions. <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">Vesiculobullous rashes</span>, as well as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, have been 
observed during drug therapy. Rare instances of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, some 
resembling <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and a few cases of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> 
have also been reported.<br>Â <br><span class="Bold">Skin and Mucous 
Membranes:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, and rare instances of exfoliative 
<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> have been reported. (See <span class="Bold"><span class="Bold"><a href="#Section_7"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></span></span>.)<br>Â <br><span class="Bold">Liver:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and abnormalities in liver function tests have 
been observed during clindamycin therapy.<br>Â <br><span class="Bold">Renal:</span> 
Although no direct relationship of clindamycin to renal damage has been 
established, renal dysfunction as evidenced by <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and/or 
<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> has been observed in rare instances.<br>Â <br><span class="Bold">Hematopoietic:</span> Transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>) and 
<span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. Reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> 
have been made. No direct etiologic relationship to concurrent clindamycin 
therapy could be made in any of the foregoing.<br>Â <br><span class="Bold">Musculoskeletal:</span> Rare instances of <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> have been 
reported.<br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-16"></a><p></p>
<h1>OVERDOSAGE</h1>Significant mortality was observed in mice at an intravenous dose of 855 mg/kg 
and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the 
mice, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were observed. <br>Â  <br>Hemodialysis and 
peritoneal dialysis are not effective in removing clindamycin from the 
serum.<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-17"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>If significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs during therapy, this antibiotic should be 
discontinued (see <span class="Bold"><a href="#section-"> WARNING</a>Â </span>box).<br><a href="http://"></a>Adults<br><span class="Bold"><span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span></span>â€”150 to 300 mg every 6 hours. 
<span class="Bold"><span class="Italics">More severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span></span>â€”300 to 
450 mg every 6 hours.Â <a href="http://"></a><a href="http://"></a><a href="http://"></a>Pediatric Patients<br><span class="Bold"><span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span></span>â€”8 to 16 mg/kg/day (4 to 8 
mg/lb/day) divided into three or four equal doses. <span class="Bold"><span class="Italics">More severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span></span>â€”16 to 20 mg/kg/day (8 to 10 
mg/lb/day) divided into three or four equal doses.<br>Â <br>To avoid the 
possibility of esophageal irritation, clindamycin hydrochloride capsules should 
be taken with a full glass of water.<br>Â <br>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to anaerobic 
bacteria are usually treated with clindamycin phosphate injection. However, in 
clinically appropriate circumstances, the physician may elect to initiate 
treatment or continue treatment with clindamycin hydrochloride 
capsules.<br>Â <br>In cases of Î²-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, treatment 
should continue for at least 10 days.<a href="http://"></a><a href="http://"></a><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-18"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Clindamycin hydrochloride capsules are available in the following 
strengths, colors and sizes:</p>
<p><span class="Bold">150 mg</span> Turquoise blue opaque cap and light green body 
printed with â€œRX692â€? on cap and body in black ink.</p>
<p>NDC 67296-0315-3 Bottles of 40</p>
<p>Store at 20 - 25Â° C (68 - 77Â° F). (See USP Controlled Room Temperature).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-19"></a><p></p>One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at 
dose levels up to 300 mg/kg/day (approximately 1.6 and 5.4 times the highest 
recommended adult human dose based on mg/m<span class="Sup">2</span>, 
respectively) have shown clindamycin to be well tolerated. No appreciable 
difference in pathological findings has been observed between groups of animals 
treated with clindamycin and comparable control groups. Rats receiving 
clindamycin hydrochloride at 600 mg/kg/day (approximately 3.2 times the highest 
recommended adult human dose based on mg/m<span class="Sup">2</span>) for 6 months 
tolerated the drug well; however, dogs dosed at this level (approximately 10.8 
times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>) <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span>, would not eat, and lost weight.</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-20"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria 
that Grow Aerobically; Approved Standard-5th ed. NCCLS document M7-A5, 2000. 
NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898.</li>
<li>NCCLS. Performance Standards for Antimicrobial Susceptibility Testing: 13th 
Informational Supplement. NCCLS document M100-S13 (M2 and M7), 2003. NCCLS, 
940 West Valley Road, Suite 1400, Wayne, PA 19087-1898.</li>
<li>NCCLS. Methods for Antimicrobial Susceptibility Testing of Anaerobic 
Bacteria 5th ed. Approved Standard. NCCLS document M11-A5, 2001. NCCLS, 940 West 
Valley Road, Suite 1400, Wayne, PA 19087-1898.</li>
<li>NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; 
Approved Standard-8th ed. NCCLS document M2-A8 (ISBN 1-56238-393-0), 2003. 
NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898.</li>
</ol>
<p class="First">Manufactured for:</p>
<p>Ranbaxy Pharmaceuticals Inc.</p>
<p>Jacksonville, FL 32257 USA</p>
<p>by: Ohm Laboratories Inc.</p>
<p>North Brunswick, NJ 08902 USA</p>
<p>November 2006</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>copy of label<div class="Figure"><img alt="copy of label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=63a0466c-af7d-4696-a950-19b73b55a65a&amp;name=6729603153.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLINDAMYCIN HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">clindamycin hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67296-0315(NDC:63304-692)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLINDAMYCIN HYDROCHLORIDE</strong> (CLINDAMYCIN) </td>
<td class="formItem">CLINDAMYCIN HYDROCHLORIDE</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (Turquoise blue) ,Â green (light green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX692</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67296-0315-3</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065442</td>
<td class="formItem">11/01/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>RedPharm Drug Inc.
							(008039641)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ohm Laboratories Inc.</td>
<td class="formItem"></td>
<td class="formItem">051565745</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>93149232-fbfa-443b-ae5b-b7302ebe5442</div>
<div>Set id: 63a0466c-af7d-4696-a950-19b73b55a65a</div>
<div>Version: 1</div>
<div>Effective Time: 20110624</div>
</div>
</div>Â <div class="DistributorName">RedPharm Drug Inc.</div></p>
</body></html>
